Aurora Completes Fundraising Drive By Closing Expanded Credit Facility – Grizzle

Aurora Completes Fundraising Drive By Closing Expanded Credit Facility - Grizzle
Aurora Cannabis Closes Expanded C$360 Million (US$280 Million) Credit Facility
EDMONTON, Sept. 9, 2019 /CNW/ – Aurora Cannabis Inc. ("Aurora or the "Company") (NYSE |TSX: ACB), the Canadian company defining the future of cannabis worldwide, is pleased to announce that it has closed its previously announced amended and upsized credit facilities with a syndicate of lenders led by the Bank of Montreal ("BMO"). The facilities consist of an additional C$160 million in term loans, as well as an accordion feature that enables Aurora to upsize the facility by approximately C$40 million, in addition to the original C$200 million in credit facilities all of which mature in 2021. The credit facilities will have a first ranking general security interest in the assets of Aurora and can be repaid without penalty at Auroras discretion.

"We are very pleased to now have three of the five largest Schedule 1 Canadian banks in our syndicate, along with increased participation from other key syndicate partners," said Terry Booth, CEO of Aurora.  "Our continued operational execution, world-class facilities, and strong corporate governance gives our financing partners the confidence to step in as an important part of the Aurora story."  

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 625,000 kg per annum and sales and operations in 25 countries across five continents, Aurora is one of the worlds largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

In addition to the Company’s rapid organic growth and strong execution on strategic M&A, which to date includes 17 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs, Whistler, Chemi Pharmaceutical, and Hempco – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI), EnWave Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty Group (private), and Wagner Dimas (private).

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high-quality consistent product. Designed to be replicable and scalable globally, our production facilities are designed to produce cannabis at significant scale, with high quality, industry-leading yields, and low-per gram production costs. Each of Auroras facilities is built to meet European Union Good Manufacturing Practices ("EU GMP") standards. Certification has been granted to Auroras first production facility in Mountain View County, the MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland. All Aurora facilities are designed and built to the EU GMP standard.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high-quality consistent product. Designed to be replicable and scalable globally, our production facilities are designed to produce cannabis at significant scale, with high quality, industry-leading yields, and low-per gram production costs. Each of Aurora’s facilities is built to meet European Union Good Manufacturing Practices (“EU GMP”) standards. Certification has been granted to Aurora’s first production facility in Mountain View County, the MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland. All Aurora facilities are designed and built to the EU GMP standard.

In addition to the Companys rapid organic growth and strong execution on strategic M&A, which to date includes 17 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs, Whistler, Chemi Pharmaceutical, and Hempco – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI), EnWave Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty Group (private), and Wagner Dimas (private).

Auroras Common Shares trade on the TSX and NYSE under the symbol "ACB", and is a constituent of the S&P/TSX Composite Index.

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 625,000 kg per annum and sales and operations in 25 countries across five continents, Aurora is one of the world’s largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX, NYSE nor their applicable Regulation Services Providers (as that term is defined in the policies of the Toronto Stock Exchange and New York Stock Exchange) accept responsibility for the adequacy or accuracy of this release.

News by QuoteMedia www.quotemedia.com Share Tags ACBAurora CannabisCanada CannabisCanadian licensed producercannabis stocks Authored By Anthony Varrell Anthony Varrell is Managing Director of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

For further information: For Media: Heather MacGregor, +1.416.509.5416, [email protected]; For Investors: Rob Kelly, +1.647.331.7228, [email protected]

The Motley Fool Canada Cannabis Stocks Buying This Weed Stock Could Be Like Buying Aurora (TSX:ACB) in 2016

When Aurora Cannabis (TSX:ACB)(NYSE:ACB) debuted, its price was $1.78. Weed upstart Supreme Cannabis (TSX:FIRE) is trading at $1.43 today, which is very close to Aurora’s price in October 2016. I can’t help but ask if FIRE will follow Aurora’s trajectory.

Aurora Cannabis, the cannabis company with the largest production capacity, has had a meteoric rise since its market debut. In one year, the stock jumped 22% to $2.18. But in just two years, the price soared to $9.28 or 421%. It was a heyday for investors who sold their shares.

For those who are still holding on to the stock, ACB’s current price is $8.02. It’s still 267.9 over the 2016 price. Analysts are projecting a potential upside of about 105% in the next 12 months. If you go by these projections, it appears that Aurora Cannabis remains as the top weed stock.

That is not surprising because, for one, Aurora could potentially produce 600,000 kilograms of cannabis annually. It has a strong presence overseas with coverage in 24 countries. Aurora’s focus is on the medical marijuana market, although it is capable of dominating the recreational market and the coming derivatives market.

Market analysts have high expectations for Supreme Cannabis. Their price forecast for this small-cap weed stock in the next 12 months is $4.50, or a gain of 214.68%. But will the company really “fire” up?

Assuming Supreme Cannabis’s production facilities are fully operational, the maximum annual yield is 50,000 kilograms, which are only 8.33% of Aurora’s annual production capacity. Notwithstanding the production capacity, Supreme Cannabis has equal chances of making it big in the cannabis industry.

The five brands of Supreme plus several partnerships could catapult FIRE to a premium cannabis lifestyle company in the world. The lead brand, 7ACRES, is transitioning from a wholesale business to premium consumer brand. That should be complete by Q3 fiscal 2020.

Supreme’s partnership with PAX Labs is a welcome development. 7ACRES is one of only four licensed producers chosen as a partner. The company will create the cannabis oil pods for PAX’s Era. The product is a market-leading vaporizer and best-selling pen-and-pod system in the U.S.

For the international market, Supreme’s opportunity is in South Africa. Medigrow, a subsidiary, will capitalize after the government’s removal of CBD from the list of highly controlled drugs. With multiple sources of growth, Supreme expects net revenue for fiscal 2020 to be between $150 million and $180 million with positive adjusted net EBITDA as well.

According to Navdeep Dhaliwal, CEO of Supreme Cannabis, capital deployment, and brand-building set the company apart. He is confident that the revenue drivers would set the company towards profitability and disciplined growth.

Supreme Cannabis is not a giant like Aurora Cannabis. But if all wheels are in motion, the stock’s rise could be similar to Aurora’s incredible climb from three years ago. Supreme Cannabis could also outperform the other small-cap weed stocks. Will you wait for the stock heat up some before buying? I hope not.

The first wave of cannabis legalization minted millionaires out of everyday investors, and it might be about to happen again.

Because when edibles are legalized in Canada on October 17th, experts project a new $2.7 BILLION market will be born.

Our last legalization stock pick is already up 1,211%, and now were recommending one tiny small-cap stock before Cannabis 2.0.